Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed.

Conditions

MSI
ColoRectal Cancer
Chemotherapy
Resistance, APC

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

Vall d'Hebron Institute of Oncology

Collaborators

[object Object]